Clinical Trial Update: Second STOP After Pioglitazone Priming in CML Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on pioglitazone priming for patients with chronic myeloid leukemia, outlining a second STOP strategy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Versailles Hospital | Conditions: Chronic Myeloid Leukemia (CML) | Phase 2 | Status: UNKNOWN